Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Prognostic value of neurotrophic growth factor (BDNF) in patients with colorectal cancer during chemotherapy
1
Department of Toxicology and Health Protection, Faculty of Health Sciences in Bytom, Medical Uniwersity of Silesia in Katowice
2
Oncological Ward, Independent Public Health Care Unit, Voivodeship Specialised Hospital No. 3, Rybnik, Poland
3
Wyższa Szkoła Biznesu w Dąbrowie Górniczej
4
Department of Pharmacology, Opole University, Opole, Poland
Corresponding author
Anna Głogowska-Gruszka
Department of Toxicology and Health Protection, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, Poland, ul. Piekarska 18, 41-902 Bytom
Department of Toxicology and Health Protection, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, Poland, ul. Piekarska 18, 41-902 Bytom
Ann. Acad. Med. Siles. 2019;73:283-292
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The brain-derived neurotrophic factor (BDNF) is a protein belonging to neurotrophins that plays a key role in the proper development and functioning of the mammalian central nervous system. Previous studies have focused on assessment of the BDNF concentration in blood serum as a potential biomarker in neurological disorders. Recently, the BDNF signalling pathway has been recognised as a potential target for anticancer drugs, while its receptor (TrkB) as an oncogene in colorectal cancer cells. Despite the significant role in carcinogenesis, there are few studies on BDNF as a biomarker in colorectal cancer.
Material and methods:
The study included 25 patients with clinically and histopathologically confirmed colorectal cancer, who were qualified for treatment. Prior to the first administration of chemotherapy, venous blood samples were collected from the patients and the biochemical parameters routinely determined prior to treatment were evaluated. Additionally, the serum BDNF concentration was determined by the immunoenzymatic method in all the patients.
Results:
The serum BDNF concentration in patients was 50.24 ± 23.37 ng/ml. The BDNF concentration did not differ significantly between women and men. A negative correlation was found between the BDNF and CRP concentration and the BDNF and LDH concentration. The BDNF levels were significantly higher in patients who underwent primary tumour resection before chemotherapy. There was no correlation between the BDNF concentration and age, gender, BMI, CEA marker and liver enzymes in patients with colorectal cancer. There was no correlation between the BDNF concentration and clinical response to the treatment.
Conclusions:
BDNF cannot be considered as a prognostic factor in patients with colorectal cancer.
The brain-derived neurotrophic factor (BDNF) is a protein belonging to neurotrophins that plays a key role in the proper development and functioning of the mammalian central nervous system. Previous studies have focused on assessment of the BDNF concentration in blood serum as a potential biomarker in neurological disorders. Recently, the BDNF signalling pathway has been recognised as a potential target for anticancer drugs, while its receptor (TrkB) as an oncogene in colorectal cancer cells. Despite the significant role in carcinogenesis, there are few studies on BDNF as a biomarker in colorectal cancer.
Material and methods:
The study included 25 patients with clinically and histopathologically confirmed colorectal cancer, who were qualified for treatment. Prior to the first administration of chemotherapy, venous blood samples were collected from the patients and the biochemical parameters routinely determined prior to treatment were evaluated. Additionally, the serum BDNF concentration was determined by the immunoenzymatic method in all the patients.
Results:
The serum BDNF concentration in patients was 50.24 ± 23.37 ng/ml. The BDNF concentration did not differ significantly between women and men. A negative correlation was found between the BDNF and CRP concentration and the BDNF and LDH concentration. The BDNF levels were significantly higher in patients who underwent primary tumour resection before chemotherapy. There was no correlation between the BDNF concentration and age, gender, BMI, CEA marker and liver enzymes in patients with colorectal cancer. There was no correlation between the BDNF concentration and clinical response to the treatment.
Conclusions:
BDNF cannot be considered as a prognostic factor in patients with colorectal cancer.
REFERENCES (32)
1.
Żełobowska K., Gumprecht J., Grzeszczak W. Neurotropowy czynnik pochodzenia mózgowego (BDNF) – udział w patogenezie insulinooporności i cukrzycy typu 2. Przew. Lek. 2007; 4: 79–83.
2.
Khan N., Smith M.T. Neurotrophins and Neuropatic Pain: Role in Pathobiology. Molecules 2015; 20(6): 10657–10688, doi: 10.3390/molecules200610657.
3.
Urbaniak A. Receptor p75NTR – rola w procesach wzrostu i śmierci komórki. Postepy Hig. Med. Dosw. 2012; 66: 304–310.
4.
Cunha C., Brambilla R., Thomas K.L. A simple role for BDNF in learning and memory? Front Mol. Neurosci. 2010; 3(1): 1–14, doi: 10.3389/neuro.001.2010. eCollection 2010.
5.
Brierley G., Priebe I, Purins L., Fung K., Tabor B., Lockett T., Nice E., Gibbs P., Tie J., McMurrick P., Moore J., Ruszkiewicz A., Burgess A., Cosgrove L.J. Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients. Cancer Biomark. 2013; 13(2): 67–73, doi: 10.3233/CBM-130345.
6.
Roesler R., de Farias C.B., Abujamra A.L., Brunetto A.L., Schwartsmann G. BDNF/TrkB signaling as anti-tumor target. Expert Rev. Anticancer Ther 2011; 11(10): 1473–1475, doi: 10.1586/era.11.150.
7.
Yang X., Martin T.A., Jiang W.G. Biological influence of brain‑derived neurotrophic factor (BDNF) on colon cancer cells. Exp. Ther. Med. 2013; 6(6): 1475–1481, doi: 10.3892/etm.2013.1330.
8.
Sarabi M., Perraud A., Mazouffre C., Nouaille M., Jauberteau MO., Mathonnet M. Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients. Biomed. Rep. 2017; 6(1): 89–94, doi: 10.3892/br.2016.801.
9.
Akil H., Perraud A., Mélin C., Jauberteau M.O., Mathonnet M. Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival. PloS One 2011; 6(9): e25097, doi: 10.1371/journal.pone.0025097. Epub 2011 Sep 26.
10.
Lommatzsch M., Zingler D., Schuhbaeck K., Schloetcke K., Zingler C., Schuff-Werner P., Virchow J.C. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005; 26(1): 115–123, doi: 10.1016/j.neurobiolaging.2004.03.002.
11.
Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003; 54(1): 70–75, doi: 1016/s0006-3223(03)00181-1.
12.
Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002; 109(2): 143–148, doi: 10.1016/s0165-1781(02)00005-7.
13.
Fujimura H., Altar CA., Chen R., Nakamura T., Nakahashi T., Kambayashi J., Sun B., Tandon N.N. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87(4): 728–734.
14.
Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 2002; 110(3): 249–257, doi: 10.1016/s0165-1781(02)00127-0.
15.
Noga O., Hanf G., Schäper C., O’Connor A., Kunkel G. The influence of inhalative corticosteroids on circulating Nerve Growth Factor, Brain-Derived Neurotrophic Factor and Neurotrophin-3 in allergic asthmatics. Clin. Exp. Allergy 2001; 31(12): 1906–1912, doi: 10.1046/j.1365-2222.2001.01249.x.
16.
Rosenfeld R.D., Zeni L., Haniu M., Talvenheimo J., Radka S.F., Bennett L., Miller J.A., Welcher A.A. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr. Purif. 1995; 6(4): 465–471, doi: 10.1006/prep.1995.1062.
17.
Ziegenhorn A.A, Schulte-Herbrüggen O., Danker-Hopfe H., Malbranc M., Hartung H.D., Anders D., Lang U.E., Steinhagen-Thiessen E., Schaub R.T., Hellweg R. Serum neurotrophins—a study on the time course and influencing factors in a large old age sample. Neurobiol. Aging 2007; 28(9): 1436–1445, doi: 10.1016/j.neurobiolaging.2006.06.011.
18.
Bus B.A., Tendolkar I., Franke B., de Graaf J., den Heijer M., Buitelaar J.K., Oude Voshaar R.C. Serum brain-derived neurotrophic factor: determinants and relationship with depressive symptoms in a community population of middle-aged and elderly people. World J. Biol. Psychiatry 2012; 13(1): 39–47, doi: 10.3109/15622975.2010.545187.
19.
Scharfman H.E., MacLusky N.J. Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. Front Neuroendocrinol 2006; 27(4): 415–435, doi: 10.1016/j.yfrne.2006.09.004.
20.
Pillai A., Bruno D., Sarreal A.S., Hernando R.T., Saint-Louis L.A., Nierenberg J., Ginsberg S.D., Pomara N., Mehta P.D., Zetterberg H., Blennow K., Buckley P.F. Plasma BDNF levels vary in relation to body weight in females. PLoS One 2012; 7(7): e39358, doi: 10.1371/journal.pone.0039358.
21.
Lang U.E., Hellweg R., Gallinat J. BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004; 29(4): 795–798, doi: 10.1038/sj.npp.1300382.
22.
Laske C., Stransky E., Eschweiler G.W., Klein R., Wittorf A., Leyhe T., Richartz E., Köhler N., Bartels M., Buchkremer G., Schott K. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J. Psychiatr. Res. 2007; 41(7): 600–605, doi: 10.1016/j.jpsychires.2006.02.007.
23.
Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003; 54(1): 70–75, doi: 10.1016/s0006-3223(03)00181-1.
24.
Tanaka K., Okugawa Y., Toiyama Y., Inoue Y., Saigusa S., Kawamura M., Araki T., Uchida K., Mohri Y., Kusunoki M. Brain-derived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer. PLoS One 2014; 9(5): e96410, doi: 10.1371/journal.pone.0096410.
25.
Brunetto de Farias C., Rosemberg D.B., Heinen T.E., Koehler-Santos P., Abujamra A.L., Kapczinski F., Brunetto A.L., Ashton-Prolla P., Meurer L., Reis Bogo M., Damin D.C., Schwartsmann G., Roesler R. BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer. Oncology 2010; 79(5-6): 430–439, doi: 10.1159/000326564.
26.
Yang Z.F., Ho D.W., Lau C.K., Tam K.H., Lam C.T., Yu W.C., Poon R.T., Fan S.T. Significance of the serum brain-derived neurotrophic factor and platelets in hepatocellular carcinoma. Oncol. Rep. 2006; 16(6): 1237–1243.
27.
Rosas-Vargas H., Martinez-Ezquerro J.D., Bienvenu T. Brain-derived neurotrophic factor, food intake regulation, and obesity. Arch. Med. Res. 2011; 42(6): 482–494, doi: 10.1016/j.arcmed.2011.09.005.
28.
Gunstad J., Schofield P., Paul R.H., Spitznagel M.B., Cohen R.A., Williams L.M., Kohn M., Gordon E. BDNF Val66Met polymorphism is associated with body mass index in healthy adults. Neuropsychobiology 2006; 53(3): 153–156, doi: 10.1159/000093341.
29.
El-Gharbawy A.H., Adler-Wailes D.C., Mirch M.C., Theim K.R., Ranzenhofer L., Tanofsky-Kraff M., Yanovski J.A. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and adolescents. J. Clin. Endocrinol. Metab. 2006; 91(9): 3548–3552, doi: 10.1210/jc.2006-0658.
30.
Stanek K., Gunstad J., Leahey T., Glickman E., Alexander T., Spitznagel M.B., Juvancic Heltzel J., Murray L. Serum brain-derived neurotrophic factor is associated with reduced appetite in healthy older adults. J. Nutr. Health Aging 2008; 12(3): 183–185, doi: 10.1007/bf02982616.
31.
Nakazato M., Hashimoto K., Shimizu E., Kumakiri C., Koizumi H., Okamura N., Mitsumori M., Komatsu N., Iyo M. Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Biol. Psychiatry 2003; 54(4): 485–490, doi: 10.1016/s0006-3223(02)01746-8.
32.
Patani N., Jiang WG., Mokbel K. Brain-derived neurotrophic factor expression predicts adverse pathological & clinical outcomes in human breast cancer. Cancer Cell. Int. 2011; 11(1): 23, doi: 10.1186/1475-2867-11-23.
Share
RELATED ARTICLE
| eISSN: | 1734-025X |
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
